Cargando…

Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is considered a critical hepatic manifestation of metabolic syndrome. Berberine (BBR) exerts anti-hyperglycemic and anti-dyslipidemic effects and can also ameliorate NAFLD. Thus, BBR might exert its therapeutic effect on NAFLD by improving glucoli...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Li, Cang, Zhen, Sun, Honglin, Nie, Xiaomin, Wang, Ningjian, Lu, Yingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329945/
https://www.ncbi.nlm.nih.gov/pubmed/28241817
http://dx.doi.org/10.1186/s12902-017-0165-7
_version_ 1782511158724395008
author Zhao, Li
Cang, Zhen
Sun, Honglin
Nie, Xiaomin
Wang, Ningjian
Lu, Yingli
author_facet Zhao, Li
Cang, Zhen
Sun, Honglin
Nie, Xiaomin
Wang, Ningjian
Lu, Yingli
author_sort Zhao, Li
collection PubMed
description BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is considered a critical hepatic manifestation of metabolic syndrome. Berberine (BBR) exerts anti-hyperglycemic and anti-dyslipidemic effects and can also ameliorate NAFLD. Thus, BBR might exert its therapeutic effect on NAFLD by improving glucolipid metabolism. Here, we investigated the aspects and extent to which glucolipid metabolism were affected by BBR in rats with NAFLD. METHODS: Three groups of Sprague–Dawley rats were studied: a control group (n = 6) fed a normal chow diet and a NAFLD group (n = 6) and a NAFLD + BBR group (n = 6) fed a high-fat diet. Normal saline and BBR (150 mg/kg body weight/day for 16 weeks) were administered by gavage. All rats were infused with isotope tracers. The rates of glucose appearance (Ra(glu)), gluconeogenesis (GNG) and glycerol appearance (Ra(gly)) were assessed with (2)H and (13)C tracers, whereas the rates of hepatic lipogenesis and fatty acid β oxidation were measured using the (3)H tracer. RESULTS: When the NAFLD model was successfully induced by administering a high-fat diet, body weight, insulin resistance and dyslipidemia were significantly increased. After the BBR treatment, weight loss, decreased lipid profiles and HOMA-IR, and increased ISI were observed. Meanwhile, BBR reduced Ra(glu), GNG and hepatic lipogenesis, whereas the rate of fatty acid β oxidation in skeletal muscle showed an increasing trend. Ra(gly) showed a decreasing trend. Based on the results of the histological analysis, BBR obviously attenuated the ectopic liver fat accumulation. CONCLUSIONS: BBR improved NAFLD by inhibiting glucogenesis and comprehensively regulating lipid metabolism, and its effect on inhibiting hepatic lipogenesis was much stronger. The improvement may be partly mediated by weight loss. Berberine might be a good choice for patients with NAFLD and glucose metabolic disorder. Future clinical trials need to be conducted to confirm these effects.
format Online
Article
Text
id pubmed-5329945
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53299452017-03-03 Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease Zhao, Li Cang, Zhen Sun, Honglin Nie, Xiaomin Wang, Ningjian Lu, Yingli BMC Endocr Disord Research Article BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is considered a critical hepatic manifestation of metabolic syndrome. Berberine (BBR) exerts anti-hyperglycemic and anti-dyslipidemic effects and can also ameliorate NAFLD. Thus, BBR might exert its therapeutic effect on NAFLD by improving glucolipid metabolism. Here, we investigated the aspects and extent to which glucolipid metabolism were affected by BBR in rats with NAFLD. METHODS: Three groups of Sprague–Dawley rats were studied: a control group (n = 6) fed a normal chow diet and a NAFLD group (n = 6) and a NAFLD + BBR group (n = 6) fed a high-fat diet. Normal saline and BBR (150 mg/kg body weight/day for 16 weeks) were administered by gavage. All rats were infused with isotope tracers. The rates of glucose appearance (Ra(glu)), gluconeogenesis (GNG) and glycerol appearance (Ra(gly)) were assessed with (2)H and (13)C tracers, whereas the rates of hepatic lipogenesis and fatty acid β oxidation were measured using the (3)H tracer. RESULTS: When the NAFLD model was successfully induced by administering a high-fat diet, body weight, insulin resistance and dyslipidemia were significantly increased. After the BBR treatment, weight loss, decreased lipid profiles and HOMA-IR, and increased ISI were observed. Meanwhile, BBR reduced Ra(glu), GNG and hepatic lipogenesis, whereas the rate of fatty acid β oxidation in skeletal muscle showed an increasing trend. Ra(gly) showed a decreasing trend. Based on the results of the histological analysis, BBR obviously attenuated the ectopic liver fat accumulation. CONCLUSIONS: BBR improved NAFLD by inhibiting glucogenesis and comprehensively regulating lipid metabolism, and its effect on inhibiting hepatic lipogenesis was much stronger. The improvement may be partly mediated by weight loss. Berberine might be a good choice for patients with NAFLD and glucose metabolic disorder. Future clinical trials need to be conducted to confirm these effects. BioMed Central 2017-02-28 /pmc/articles/PMC5329945/ /pubmed/28241817 http://dx.doi.org/10.1186/s12902-017-0165-7 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Zhao, Li
Cang, Zhen
Sun, Honglin
Nie, Xiaomin
Wang, Ningjian
Lu, Yingli
Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease
title Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease
title_full Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease
title_fullStr Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease
title_full_unstemmed Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease
title_short Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease
title_sort berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329945/
https://www.ncbi.nlm.nih.gov/pubmed/28241817
http://dx.doi.org/10.1186/s12902-017-0165-7
work_keys_str_mv AT zhaoli berberineimprovesglucogenesisandlipidmetabolisminnonalcoholicfattyliverdisease
AT cangzhen berberineimprovesglucogenesisandlipidmetabolisminnonalcoholicfattyliverdisease
AT sunhonglin berberineimprovesglucogenesisandlipidmetabolisminnonalcoholicfattyliverdisease
AT niexiaomin berberineimprovesglucogenesisandlipidmetabolisminnonalcoholicfattyliverdisease
AT wangningjian berberineimprovesglucogenesisandlipidmetabolisminnonalcoholicfattyliverdisease
AT luyingli berberineimprovesglucogenesisandlipidmetabolisminnonalcoholicfattyliverdisease